Co-Diagnostics Acquires Commercialization Rights for Mathematically Enhanced Primers with 2.5 Million Fold Improvement in Specificity

Cooperative Primers is a mathematically-engineered technology that improves specificity in PCR reactions up to 2.5 million fold.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Salt Lake City, Utah (PRWEB) January 02, 2014

Co-Diagnostics announced today that it signed a letter of intent with DNA Logix to acquire its Cooperative Primer technology – the subject of a paper published on December 26, 2013 in the Journal of Molecular Diagnostics. Cooperative Primers is a mathematically-engineered technology that improves specificity in PCR reactions up to 2.5 million fold. It is the latest in a series of technologies developed by DNA Logix to be acquired by Co-Diagnostics. The letter of intent also includes provisions to acquire all future developments by DNA Logix over the next 5 years.

“The DNA Logix staff has repeatedly used advanced mathematics to develop game changing technology in the field of DNA diagnostics,” said Dwight Egan, CEO of Co-Diagnostics. “Our investment in them shows our commitment to advancing the boundaries of what is possible in this field. We are excited to have them join our R&D team.”

About Co-Diagnostics

Co-Diagnostics, Inc., a molecular diagnostics company, is a Utah corporation based in Sandy, Utah that develops, manufactures and markets fully integrated DNA test systems. The Company’s intellectual property is based on mathematical principles that create algorithms in a unique DNA-based diagnostics system that is superior in cost and speed of development to all other such systems, both in the US and abroad.

http://www.codiagnostics.com


Contact